Skip to main content

Drug Price Debate Might Not Hinder Biotech ETFs

By: ETFdb
The issue of pharmaceuticals pricing reform — a long-time favorite discussion on Capitol Hill — is gaining momentum, and some healthcare assets are bearing that burden.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.